GENET archive


5-Animals: Genzyme receives Japanese patent in gene pharming

mailinglist genet-news
-------------------------- GENET-news ---------------------------

TITLE:  Genzyme Transgenics Receives Japanese Patent for the
        Production of Therapeutic Proteins in Milk of Transgenic
SOURCE: Genzyme ,
DATE:   May 13, 1999

----------------- archive: ------------------

Genzyme Transgenics Receives Japanese Patent for the Production
of Therapeutic Proteins in Milk of Transgenic Animals

-- Milestone payment to be received from Asian joint venture
partner --

Genzyme Transgenics Corporation announced today receipt of Patent
No. 2874751 from the Japanese Patent Office for the production of
transgenic animals secreting desired proteins into milk. The
patent covers the basic DNA sequences which link a milk protein
promoter with a gene encoding the protein of interest, as well as
the fundamental method used to produce therapeutic proteins in
the milk of transgenic animals. In 1996, Genzyme Transgenics
Corp. received a similarly broad patent in Europe for the
production of proteins in the milk of transgenic animals. Genzyme
Transgenics and Sumitomo Metal Industries, Ltd. formed a joint
venture, known as SMI Genzyme (SMIG), for the commercialization
of transgenic technology in Asia. As part of the joint venture
agreement, SMIG will make a $500,000 milestone payment to Genzyme
Transgenics for issuance of the Japanese patent.

"This patent, providing broad protection for transgenic protein
production in Japan, provides a strong base for both the company
and its partners to commercialize transgenic technology and
transgenically produced therapeutic proteins in Asia," said
Sandra Nusinoff Lehrman, M.D., president and chief executive
officer of Genzyme Transgenics. Other recent Genzyme Transgenics
patents include the right to produce antibodies at commercial
levels in the milk of transgenic animals and to produce
recombinant human antithrombin III in the milk of goats.
Recombinant human antithrombin III, a protein that helps to
regulate blood clotting, is in Phase III trials in heparin
resistant patients undergoing cardiopulmonary bypass. Genzyme
Transgenics Corporation applies transgenic technology to enable
the development and production of recombinant proteins and
monoclonal antibodies for medical uses. Primedica Corporation
provides preclinical development and testing services to
pharmaceutical, biotechnology, medical device and other
companies. Genzyme Transgenics Corporation is also developing
idiotypic vaccines in collaboration with the National Cancer

This news release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to a number of risks,
uncertainties and other factors that could cause actual results
to differ materially from future results expressed or implied by
such statements. Factors that may cause such differences include,
but are not limited to, the uncertainties associated with product
development, the risk that clinical trials will not commence when
planned, and the risks and uncertainties associated with
dependence upon the actions of government and regulatory


-| Hartmut Meyer
-| Co-ordinator
-| The European NGO Network on Genetic Engineering
-| Reinhaeuser Landstr. 51
-| D - 37083 Goettingen
-| Germany
-| phone: #49-551-7700027
-| fax  : #49-551-7701672
-| email:

Genet News